Idera Pharmaceuticals, Inc. (IDRA)
-NasdaqCM 0.55 
0.16(22.14%) 3:59PM EDT|After Hours
:
0.55 0.00 (0.02%) 4:01PM EDT - Nasdaq Real Time Price
| Prev Close: | 0.70 |
|---|
| Open: | 0.58 |
|---|
| Bid: | 0.54 x 900 |
|---|
| Ask: | 0.55 x 100 |
|---|
| 1y Target Est: | 2.00 |
|---|
| Beta: | 2.31 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.52 - 0.59 |
|---|
| 52wk Range: | 0.19 - 1.22 |
|---|
| Volume: | 978,996 |
|---|
| Avg Vol (3m): | 83,115 |
|---|
| Market Cap: | 15.06M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.81 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements andEDGAR Online(Thu 9:04AM EDT)
- Idera Pharmaceuticals raises $16.5M in a common stock and warrant offeringtheflyonthewall.com(Thu 6:01AM EDT)
- Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and WarrantsBusiness Wire(Wed, May 1)
- Idera Pharmaceuticals files to sell $12.5M in common stock and warrantstheflyonthewall.com(Tue, Apr 23)
- IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements andEDGAR Online(Mon, Apr 22)
- Idera Announces Clinical Development Progress in Its Autoimmune Diseases ProgramBusiness Wire(Mon, Apr 1)
- IDERA PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Thu, Mar 14)
- Idera stock plummets 20 percent as company faces possible liquidationat bizjournals.com(Wed, Mar 13)
- New Star Analyst Rankings for Idera Pharmaceuticals, Inc.StarMine(Tue, Mar 12)
- Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Update on Autoimmune Disease ProgramBusiness Wire(Mon, Mar 11)
- IDERA PHARMACEUTICALS, INC. Files SEC form 10-K, Annual ReportEDGAR Online(Mon, Mar 11)
- Idera Announces Presentation at AAD Annual Meeting Demonstrating Toll-like Receptor Antagonists Normalize Expression of Inflammatory Genes in Psoriasis ModelBusiness Wire(Sat, Mar 2)
- Idera Pharmaceuticals Announces Presentation at American Academy of Dermatology Annual MeetingBusiness Wire(Tue, Feb 26)
- IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Other EventsEDGAR Online(Mon, Feb 11)
- Idera to Present at the 15th Annual BIO CEO and Investor ConferenceBusiness Wire(Tue, Feb 5)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 379.41 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.81 |
|---|
| Quarterly EPS Est
(Mar-13)
: | -0.19 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, engages in the discovery and development of novel synthetic DNA- and RNA- based drug candidates.
View More